Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms
Foreign companies with R&D in China may also benefit from deal opening up PCT search options
After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016
Seattle Genetics is demanding rights to Daiichi Sankyo’s potential blockbuster cancer treatment, which it says is an improvement on the proprietary technology included in their previous partnership
Invention patents had a coin flip chance of full invalidation by CNIPA over the past decade, but the past three years show a higher survival rate
As medical treatments become increasingly bespoke, we reveal some best practices to help inventors secure the highest quality patents possible.
In a big win for patent owners, the first-of-its-kind ruling upholds biotech innovators’ rights to collect royalties on saved GM seeds
The growing importance of rare disease treatments has strategic, commercial and potential political ramifications for life sciences IP
Centrient’s head of IP lifts the lid on why the company has been putting more focus on IP enforcement in India and explains the attractions of trade secrets
Numbers also show that damages are rising. But litigation statistics only tell part of the story on plaintiff success.
Proprietary information and data are vital sources of commercial advantage for biopharma companies, so keeping them safe is a vitally important task
Appellate court overturns PTAB invalidation, citing uncertainties of R&D in the lucrative cancer space, as well as lack of data in prior art
The number of grants also drops while UK sees worrying fall in applications; but study has good news for EPO President Campinos
Pharma patent litigation settlements involving the transfer of “anything of value” to the generic are now presumed anti-competitive under Golden State law
Delhi court refuses to extend chairman’s tenure, leaving the body with just one expert on staff and a growing backlog